Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

INSIDE INFORMATION

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE COMPANY'S H SHARE FULL CIRCULATION

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**Inside Information Provisions**").

Reference is made to the announcements of the Company dated 29 September 2025 and 1 April 2026 (the "**Announcements**") respectively, in relation to, among other things, the application for the H Share Full Circulation by the Company and the issuance of filing notice by the CSRC in respect of the H Share Full Circulation by the Company. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The Board is pleased to announce that on 18 November 2026, the Company received the approval granted by the Stock Exchange for the listing of and permission to deal in 48,300,000 H Shares, representing the maximum number of the Unlisted Shares to be converted under the conversion and listing.

SHAREHOLDING STRUCTURE

The conversion and listing will involve a total of nine participating shareholders of the Company (the "**Participating Shareholders**") holding an aggregate of 48,300,000 Unlisted Shares (the "**Converted H Shares**"). Upon the completion of the conversion and listing, the shares converted by the Participating Shareholders is as follows:

The shareholdings of the Participating Shareholders in the Company in respect of the H Share Full Circulation are set out as follows:

Name of Participating Shareholders	**Number of Converted H Shares**	**Approximate percentage of total issued Shares upon completion of the conversion and listing**
Tianjin Yangfan No.1 Enterprise Management Consulting Partnership (Limited Partnership) (天津揚帆一號企業管理諮詢合夥企業(有限合夥))	7,450,000	0.16%
Tianjin Yangfan No.2 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆二號企業管理諮詢合夥企業(有限合夥))	4,800,000	0.11%

Name of Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued Shares upon completion of the conversion and listing
Tianjin Yangfan No.3 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆三號企業管理諮詢合夥企業(有限合夥))	5,000,000	0.11%
Tianjin Yangfan No.4 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆四號企業管理諮詢合夥企業(有限合夥))	5,050,000	0.11%
Tianjin Yangfan No.5 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆五號企業管理諮詢合夥企業(有限合夥))	5,700,000	0.12%
Tianjin Yangfan No.6 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆六號企業管理諮詢合夥企業(有限合夥))	4,750,000	0.10%
Tianjin Yangfan No.7 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆七號企業管理諮詢合夥企業(有限合夥))	4,900,000	0.11%
Tianjin Yangfan No.8 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆八號企業管理諮詢合夥企業(有限合夥))	5,350,000	0.12%

Name of Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued Shares upon completion of the conversion and listing
Tianjin Yangfan No.9 Enterprise Management Consulting Partnership (Limited Partnership (天津揚帆九號企業管理諮詢合夥企業(有限合夥))	5,300,000	0.12%
Total	**48,300,000**	**1.06%**

The shareholding structure of the Company as at the date of this announcement and upon the completion of the conversion and listing is set out as follows:

	As at the date of this announcement		Upon the completion of the conversion and listing	
Types of Shares	Number of Shares	Approximate percentage of total issued Shares	Number of Shares	Approximate percentage of total issued Shares
Unlisted Shares	48,300,000	1.06%	0	0.00%
H Shares	4,522,332,324	98.94%	4,570,632,324	100.00%
Total	**4,570,632,324**	**100.00%**	**4,570,632,324**	**100.00%**

The Company will complete the relevant procedures related to the conversion of H Shares. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the conversion and listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

The H Share Full Circulation is subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

Weihai, Shandong, the PRC, 20 November 2026

As at the date of this announcement, the Board comprises:

Executive Directors
Mr. Long Jing *(Chairman)*
Mr. Cong Rinan *(Chief Executive Officer)*
Mr. Lu Junqiang
Mr. Wang Daoming

Non-executive Directors
Mr. Chen Lin
Mr. Tang Zhengpeng

Independent non-executive Directors
Mr. Li Guohui
Mrs. Meng Hong
Mr. Li Qiang
Mr. Sun Heng

* *for identification purpose only*